110 related articles for article (PubMed ID: 8460449)
1. Cell and tumor markers' immunohistochemistry in transitional cell carcinoma of the bladder.
Lopez-Beltran A; Croghan GA; Croghan I; Gaeta JF
Urol Int; 1993; 50(2):61-4. PubMed ID: 8460449
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in survival of bladder cancer.
Lopez-Beltran A; Croghan GA; Croghan I; Huben RP; Mettlin C; Gaeta JF
Cancer; 1992 Aug; 70(4):799-807. PubMed ID: 1643611
[TBL] [Abstract][Full Text] [Related]
3. Behavior of epithelial differentiation antigens (carcinoembryonic antigen, epithelial membrane antigen, keratin and cytokeratin) in transitional cell carcinomas of the bladder.
Sánchez-Fernández de Sevilla MC; Morell-Quadreny L; Gil-Salom M; Pérez-Bacete M; Fenollosa-Entrena B; Llombart-Bosch A
Urol Int; 1992; 48(1):14-9. PubMed ID: 1376008
[TBL] [Abstract][Full Text] [Related]
4. Prognostication of bladder carcinoma by immunohistochemistry: refined and combined analysis of staining for MCA and CA50.
Lipponen PK; Eskelinen MJ; Collan Y
Urol Int; 1990; 45(6):361-6. PubMed ID: 2288054
[TBL] [Abstract][Full Text] [Related]
5. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
6. Epithelial membrane antigen as an immunohistochemical marker for transitional cell carcinoma of the urinary bladder.
Takashi M; Murase T; Kinjo T; Mitsuya H; Nagura H
Urol Int; 1987; 42(3):170-5. PubMed ID: 3303592
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
Wolf HK; Stöber C; Hohenfellner R; Leissner J
Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and immunologic diagnosis of cancer. Renal and transitional carcinomas.
Cordon-Cardo C
Tumour Biol; 1987; 8(2-3):94-102. PubMed ID: 3329405
[No Abstract] [Full Text] [Related]
9. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
[TBL] [Abstract][Full Text] [Related]
10. Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers.
Muraoka K; Nabeshima K; Murayama T; Biswas C; Koono M
Int J Cancer; 1993 Aug; 55(1):19-26. PubMed ID: 8344748
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical determination of antigen 19-9 (CA 19-9) in transitional carcinoma of the bladder].
Casetta G; Cavallini A; Piana P; Squintone L; Vottero M; Tizzani A
Minerva Urol Nefrol; 1992; 44(3):169-72. PubMed ID: 1492266
[TBL] [Abstract][Full Text] [Related]
12. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
13. Enhanced detection of bladder cancer using the epithelial surface marker epithelial membrane antigen: a preliminary report.
Ring KS; Karp F; Benson MC
J Occup Med; 1990 Sep; 32(9):904-9. PubMed ID: 2074517
[TBL] [Abstract][Full Text] [Related]
14. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
[TBL] [Abstract][Full Text] [Related]
15. [Studies on multiple mucosal biopsy in patients with bladder cancer. 4. Evaluation of Thomsen-Friedenreich antigen in multiple mucosal biopsy and transitional cell carcinoma of the bladder].
Igawa M
Hinyokika Kiyo; 1986 Nov; 32(11):1663-76. PubMed ID: 3825815
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical distribution of epithelial membrane antigen in bladder carcinomas as detected with a monoclonal antibody.
Asamoto M; Fukushima S; Oosumi H; Tatemoto Y; Mori M
Urol Res; 1989; 17(5):273-7. PubMed ID: 2683314
[TBL] [Abstract][Full Text] [Related]
17. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis.
Nguyen PL; Swanson PE; Jaszcz W; Aeppli DM; Zhang G; Singleton TP; Ward S; Dykoski D; Harvey J; Niehans GA
Am J Clin Pathol; 1994 Feb; 101(2):166-76. PubMed ID: 7906919
[TBL] [Abstract][Full Text] [Related]
19. Tumor collagenase stimulating factor (TCSF) and tumor autocrine motility factor (TAMF) in bladder cancer.
Javadpour N; Guirguis R
Prog Clin Biol Res; 1991; 370():393-8. PubMed ID: 1924475
[No Abstract] [Full Text] [Related]
20. Prognostic factors in bladder cancer. A pathologic, immunohistochemical, and DNA flow-cytometric study.
Lopez-Beltran A; Croghan GA; Croghan I; Matilla A; Gaeta JF
Am J Clin Pathol; 1994 Jul; 102(1):109-14. PubMed ID: 8037155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
